Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Hassle-free stroke prevention offered by new drug, Stanford researcher says

21.11.2003


People who take a commonly prescribed yet problematic drug called Coumadin to prevent stroke or blood clots may soon have a hassle-free alternative, according to research at Stanford University School of Medicine. Results from a 7,329-person international study have found that a new drug called ximelegatran prevents strokes as effectively as Coumadin without the side effects or inconvenience.



"We think this will result in a huge shift in anti-coagulation therapy," said Gregory Albers, MD, professor of neurology and neurological sciences and director of the Stanford Stroke Center. Albers was a member of the steering committee that designed and directed the trial. Results from the 3,407-person international phase of the study will be published in the Nov. 22 issue of The Lancet. Albers and his colleagues presented results from the 3,922-person North American study at the American Heart Association meeting Nov. 11 in Orlando.

Coumadin effectively thins the blood and prevents strokes in people with a type of erratic heartbeat called atrial fibrillation. The problem is that the drug has a very narrow effective dose range – too little and it doesn’t work, too much and a person bleeds excessively. The drug also interacts with other medications and with food. Because of these complications, people on Coumadin must have their blood checked and dose adjusted regularly to make sure they are protected from stroke.


"Coumadin is very effective, but more than half of the people who should be receiving it don’t take the medication because of the inconvenience," Albers said.

In contrast, ximelegatran is just as effective as Coumadin but doesn’t require blood tests for dose adjustment and doesn’t interact with medications or food. "It’s essentially one-dose-fits-all," Albers said.

Called the Stroke Prevention Using an Oral Thrombin Inhibitor in Atrial Fibrillation, or SPORTIF, the studies comparing ximelegatran to Coumadin took place in 25 countries. They included 7,329 patients who were treated with one of the two drugs for an average of nearly two years. These were the largest trials ever conducted on people with atrial fibrillation, Albers said.

During the trials, people in the two groups had similar rates of stroke or death, though those taking ximelegatran had fewer major bleeding incidents. Albers said the most important difference was that patients on Coumadin required constant dose adjustment while those on ximelegatran took the same dose throughout the trial.

Albers said that about 6 percent of people on ximelegatran had elevated levels of liver enzymes in the period between two to six months of treatment. This side effect usually disappeared without any consequences, but he said people on ximelegatran will need to have their liver function monitored during the first few months of therapy.

Albers said he expects ximelegatran to be approved by the U.S. Food and Drug Administration within the next year. It will be sold by the pharmaceutical company AstraZeneca under the brand name Exanta. Albers served as a consultant for AstraZeneca during the trial.


Stanford University Medical Center integrates research, medical education and patient care at its three institutions – Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children’s Hospital at Stanford. For more information, please visit the Web site of the medical center’s Office of Communication & Public Affairs at http://mednews.stanford.edu.

Amy Adams | EurekAlert!
Further information:
http://mednews.stanford.edu

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>